Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a biological product manufacturing company that describes its mission as building the tools that make biology easier to engineer. The DNA stock news page on Stock Titan aggregates company announcements, collaborations, and regulatory updates so investors and observers can follow how Ginkgo’s platform is being applied across sectors.
According to Ginkgo’s public statements, its business spans cell engineering services, biosecurity offerings, modular lab automation, large-scale biological data generation, and agricultural biologicals R&D. News about Ginkgo Bioworks often covers new partnerships with academic institutions, biotechnology companies, and government agencies, as well as updates on projects funded by U.S. health and research organizations. These stories illustrate how the company’s R&D Solutions, Automation, Datapoints, Agriculture, and Biosecurity units are used in real-world programs.
Typical Ginkgo Bioworks news items include announcements of research collaborations in areas like cancer screening, drug safety modeling, and in vivo cell and gene therapy; contracts for high-throughput phenotyping platforms and biosecurity-related capabilities; and agreements to optimize fermentation and bioprocesses for agricultural soil amendments and biological crop solutions. Investors can also find information about extended strategic partnerships in agriculture and other markets.
This page may also surface press releases tied to quarterly financial results, conference presentations, and other investor communications referenced in the company’s filings. By reviewing the DNA news feed, users can see how Ginkgo Bioworks positions its platform, how its collaborations evolve over time, and how its activities relate to the broader biological product manufacturing and synthetic biology landscape.
IARPA, Ginkgo Bioworks (NYSE: DNA), and Draper have successfully completed the FELIX program, aimed at enhancing biodetection capabilities for genetically engineered organisms. The collaboration resulted in the development of advanced computational tools, particularly ENDAR software, which enables the detection of engineered DNA in complex biological samples. This breakthrough promises to transform national biosecurity efforts by providing faster, more accurate monitoring. Results will be presented on October 17, 2022, at 11 am Eastern on YouTube.
Ginkgo Bioworks (NYSE: DNA) announced a collaboration with Merck to develop up to four engineered enzymes for drug manufacturing. This partnership leverages Ginkgo's expertise in biocatalysis and enzyme optimization, aiming to enhance Merck's pharmaceutical production efficiency. The agreement includes an upfront research fee and potential milestone payments totaling up to $144 million. Ginkgo's innovative approach focuses on utilizing fungal strains for enzyme expression, which may lower production costs and improve supply chain resilience.
Ginkgo Bioworks (NYSE: DNA) announced the acquisition of Circularis, a biotechnology firm specializing in circular RNA and promoter screening technologies. This acquisition aims to enhance Ginkgo's capabilities in cell and gene therapy, particularly in RNA therapeutics, by leveraging Circularis's platform for high-throughput screening of gene expression regulatory elements. The move is expected to strengthen Ginkgo’s offerings across various biopharmaceutical applications, including collaborations with industry leaders like Biogen and Moderna.
Ginkgo Bioworks (NYSE: DNA) has announced the acquisition of Altar, a French biotechnology firm specializing in adaptive laboratory evolution (ALE). This strategic tuck-in acquisition aims to enhance Ginkgo's capabilities by integrating Altar's automated ALE instruments into its Foundry, supporting a range of industries including food, biofuels, and healthcare. Ginkgo's partnership with Altar has been fruitful, and the integration is expected to improve strain engineering for various applications, addressing challenges in creating optimized microorganisms under industrial conditions.
The White House has announced the appointment of Renee Wegrzyn, PhD, as the first Director of the Advanced Research Projects Agency for Health (ARPA-H). Currently serving as Vice President for Business Development at Ginkgo Bioworks (NYSE: DNA), Dr. Wegrzyn aims to propel transformative health breakthroughs. Her background includes significant contributions to biosecurity and synthetic biology. Established in March 2022, ARPA-H is designed to tackle challenging health issues through innovative research.
Ginkgo Bioworks (NYSE: DNA) announced the appointment of Behzad Mahdavi as Senior Vice President of Biopharma Manufacturing and Life Sciences Tools. Dr. Mahdavi brings over 20 years of experience in biopharmaceuticals and cell therapies, previously serving as VP at Catalent Pharma Solutions. His role will focus on expanding Ginkgo's market presence in bio-reagents and gene therapies. Ginkgo aims to leverage its expertise in custom organism design and enzyme discovery to enhance biopharma innovation, backed by collaborations with industry leaders.
Ayana Bio has appointed Frank Jaksch as CEO, a veteran in the health and wellness industry, particularly known for founding ChromaDex, which develops the NAD product Tru Niagen (Nasdaq: CDXC). Launched in September 2021, Ayana Bio utilizes innovative plant cell technology to produce sustainable bioactives for consumer products, aiming to address challenges in ingredient supply chains exacerbated by climate change and geopolitical issues. The company, supported by Ginkgo Bioworks (NYSE: DNA), is positioned to revolutionize sourcing through standardized cultivation methods.
Ginkgo Bioworks (NYSE: DNA) has acquired epidemiological data assets from Baktus, Inc. This transaction will enhance Ginkgo's biosecurity platform and expand its epidemic tracking and modeling services. The acquisition includes proprietary datasets and analytic tools aimed at improving public health responses to epidemics. Baktus will continue independent operations while contributing ongoing epidemiological projects and expertise to Ginkgo's Concentric initiative, further advancing biosecurity infrastructure.
Ginkgo Bioworks reported impressive Q2 2022 results, with total revenue of $145 million, signifying a 231% increase year-over-year. The company added 13 new Cell Programs, an 86% growth compared to Q2 2021. Foundry revenue reached $44 million, up 105% year-over-year, while Biosecurity revenue amounted to $100 million. Ginkgo's cash balance stands at approximately $1.4 billion, enabling future growth opportunities, including the acquisitions of Zymergen and Bayer’s West Sacramento operations. The company revised its 2022 total revenue guidance to $425–$440 million.
Summary not available.